,panitumumab,trastuzumab deruxtecan
astrazeneca,amgen,takeda,daiichi sankyo
['mbc', 'destiny-04', 'sarcoma', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm', 'reecur']
 #asco22 plenary session highlights paradigm: 1l mcrc left-side pani+mfolfox6 reecur: hd ifo better than tc in r ewing sarcoma destiny-04: t-dxd for hr+/- her2low mbc hormone resistant #oncology #mir #practicechanging 
Medical Oncologist MD, BSc Vall d'Hebrón @vallhebron @VHIO

President Secció Metges MIR del COMB @COMBarcelona 

Asesor en @SalutUIC

#oncology #research #MIR